Axsome Therapeutics
New York
About Axsome Therapeutics
Axsome Therapeutics is a biopharmaceutical company developing novel therapies for the treatment of pain and other neurological diseases. By focusing on this therapeutic area, Axsome is addressing growing markets where current treatment options are limited or inadequate. Axsome has a balanced portfolio of clinical development stage as well as research stage products. Axsome Therapeutics aims to become a fully integrated biopharmaceutical company that develops and commercializes differentiated products which increase the armamentarium of caregivers and improve the lives of patients. While the focus of the company is on developing its internally derived product candidates, Axsome also evaluates potential in-licensing opportunities to supplement its current portfolio.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 501 – 1,000
- Estimated revenue: $100K – $500K
- Total funding: $1.0B
- Funding stage: IPO
- Last round: Post-IPO Debt (May 2025)
- Ticker: nasdaq:AXSM
- Website: axsome.com
- Phone: +1 (212) 203-5072
Industries & Categories
Biopharma, Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/axsome-therapeutics-46133 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.